Islet Autoantibodies

Current Diabetes Reports

Volumn 16, Issue 6, 2016, Pages

  Lampasona, Vito ^a   Liberati, Daniela ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Autoantibodies; GAD65; IA 2; Insulin; T1D; ZnT8

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; EPITOPE; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; IA 2 ANTIBODY; INSULIN; INSULIN ANTIBODY; MEMBRANE PROTEIN; PANCREAS ISLET CELL ANTIBODY; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN PHOSPHATASE LIKE IA 2; PROTEIN ZNT8; UNCLASSIFIED DRUG; ZNT8 ANTIBODY; BIOLOGICAL MARKER;

AGE; GENETICS; HISTORY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; IPEX SYNDROME; PHENOTYPE; POLYENDOCRINOPATHY; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SEROCONVERSION; STANDARDIZATION; STIFF MAN SYNDROME; TISSUE DISTRIBUTION; ANIMAL; IMMUNOLOGY; PANCREAS ISLET;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; BIOMARKERS; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN; ISLETS OF LANGERHANS;

EID: 84964499658     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-016-0738-2     Document Type: Review

References (108)

1. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes. 1965;14:619–33. doi:10.2337/diab.14.10.619.
2. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet. 1974;2:1279–83.
3. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med. 1986;314:1360–8. doi:10.1056/NEJM198605223142106.
4. Winter WE, Pittman D. The clinical application of islet autoantibody testing for the diagnosis of autoimmune diabetes. MLO. Med Lab Obs. 2013;45:16, 20, 22 passim.
5. Bonifacio E. Predicting type 1 diabetes using biomarkers. Diabetes Care. 2015;38:989–96. doi:10.2337/dc15-0101.
6. Mujtaba MA, Fridell J, Book B, Faiz S, Sharfuddin A, Wiebke E, et al. Re-exposure to beta cell autoantigens in pancreatic allograft recipients with preexisting beta cell autoantibodies. Clin Transplant. 2015;29:991–6. doi:10.1111/ctr.12619.
7. Piemonti L, Everly MJ, Maffi P, Scavini M, Poli F, Nano R, et al. Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes. Diabetes. 2013;62:1656–64. doi:10.2337/db12-1258.
8. Knip M, Akerblom HK, Becker D, Dosch H-M, Dupre J, Fraser W, et al. Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial. JAMA. 2014;311:2279–87. doi:10.1001/jama.2014.5610.
9. Lernmark A, Molenaar JL, van Beers WA, Yamaguchi Y, Nagataki S, Ludvigsson J, et al. The Fourth International Serum Exchange Workshop to standardize cytoplasmic islet cell antibodies. The Immunology and Diabetes Workshops and Participating Laboratories. Diabetologia. 1991;34:534–5.
10. Bingley PJ, Bonifacio E, Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes. 2003;52:1128–36.
11. Greenbaum C, Palmer J, Kuglin B, Kolb H. Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of Insulin Autoantibody Measurement. J Clin Endocrinol Metab. 1992;74:1040–4. doi:10.1210/jc.74.5.1040.
12. Schmidli RS, Colman PG, Bonifacio E, Bottazzo GF, Harrison LC. High level of concordance between assays for glutamic acid decarboxylase antibodies. The First International Glutamic Acid Decarboxylase Antibody Workshop. Diabetes. 1994;43:1005–9. doi:10.2337/diabetes.43.8.1005.
13. Verge CF, Stenger D, Bonifacio E, Colman PG, Pilcher C, Bingley PJ, et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes. 1998;47:1857–66.
14. Liu E, Eisenbarth GS. Accepting clocks that tell time poorly: fluid-phase versus standard ELISA autoantibody assays. Clin Immunol. 2007;125:120–6. doi:10.1016/j.clim.2007.08.005.
15. Lampasona V, Schlosser M, Mueller PW, Williams AJK, Wenzlau JM, Hutton JC, et al. Diabetes antibody standardization program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8. Clin Chem. 2011;57:1693–702. doi:10.1373/clinchem.2011.170662.
16. Brooking H, Ananieva-Jordanova R, Arnold C, Amoroso M, Powell M, Betterle C, et al. A sensitive non-isotopic assay for GAD65 autoantibodies. Clin Chim Acta. 2003;331:55–9. doi:10.1016/S0009-8981(03)00088-3.
17. Miao D, Guyer KM, Dong F, Jiang L, Steck AK, Rewers M, et al. GAD65 autoantibodies detected by electrochemiluminescence assay identify high risk for type 1 diabetes. Diabetes. 2013;62:4174–8. doi:10.2337/db13-0534.
18. Palmer J, Asplin C, Clemons P, Lyen K, Tatpati O, Raghu P, et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science (80-). 1983;222:1337–9. doi:10.1126/science.6362005.
19. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature. 1990;347:151–6.
20. Rabin DU, Pleasic SM, Palmer-Crocker R, Shapiro JA. Cloning and expression of IDDM-specific human autoantigens. Diabetes. 1992;41:183–6. doi:10.2337/diabetes.41.2.183.
21. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A. 2007;104:17040–5. doi:10.1073/pnas.0705894104.
22. Kaufman DL, Erlander MG, Clare-Salzler M, Atkinson MA, Maclaren NK, Tobin AJ. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest. 1992;89:283–92. doi:10.1172/JCI115573.
23. Wasmeier C, Hutton JC. Molecular cloning of phogrin, a protein-tyrosine phosphatase homologue localized to insulin secretory granule membranes. J Biol Chem. 1996;271:18161–70. doi:10.1074/jbc.271.30.18161.
24. McLaughlin K, Richardson CC, Ravishankar A, Feltbower R, Morgan D, Christie M. Identification of tetraspanin-7 as a target of autoantibodies in type 1 diabetes. Diabetes. 2016. doi:10.2337/db15-1058.
25. Fenalti G, Law RHP, Buckle AM, Langendorf C, Tuck K, Rosado CJ, et al. GABA production by glutamic acid decarboxylase is regulated by a dynamic catalytic loop. Nat Struct Mol Biol. 2007;14:280–6. doi:10.1038/nsmb1228.
26. Kass I, Hoke DE, Costa MGS, Reboul CF, Porebski BT, Cowieson NP, et al. Cofactor-dependent conformational heterogeneity of GAD65 and its role in autoimmunity and neurotransmitter homeostasis. Proc Natl Acad Sci. 2014;111:E2524–9. doi:10.1073/pnas.1403182111.
27. Wei J, Jin Y, Wu H, Sha D, Wu J-Y. Identification and functional analysis of truncated human glutamic acid decarboxylase 65. J Biomed Sci. 2003;10:617–24.
28. Erdö SL. GABA outside the CNS. Springer Berlin Heidelberg; 2012.
29. Mally MI, Cirulli V, Otonkoski T, Soto G, Hayek A. Ontogeny and tissue distribution of human GAD expression. Diabetes. 1996;45:496–501. doi:10.2337/diabetes.45.4.496.
30. Kanaani J, Cianciaruso C, Phelps EA, Pasquier M, Brioudes E, Billestrup N, et al. Compartmentalization of GABA synthesis by GAD67 differs between pancreatic beta cells and neurons. PLoS One. 2015;10:e0117130. doi:10.1371/journal.pone.0117130.
31. Gotter J, Brors B, Hergenhahn M, Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med. 2004;199:155–66. doi:10.1084/jem.20031677.
32. Piquer S, Belloni C, Lampasona V, Bazzigaluppi E, Vianello M, Giometto B, et al. Humoral autoimmune responses to glutamic acid decarboxylase have similar target epitopes and subclass that show titer-dependent disease association. Clin Immunol. 2005;117:31–5. doi:10.1016/j.clim.2005.06.009.
33. Bonifacio E, Lampasona V, Bernasconi L, Ziegler AG. Maturation of the humoral autoimmune response to epitopes of GAD in preclinical childhood type 1 diabetes. Diabetes. 2000;49:202–8.
34. Solimena M, Folli F, Denis-Donini S, Comi GC, Pozza G, De Camilli P, et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med. 1988;318:1012–20. doi:10.1056/NEJM198804213181602.
35. Saiz A, Blanco Y, Sabater L, González F, Bataller L, Casamitjana R, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008;131:2553–63. doi:10.1093/brain/awn183.
36. McKeon A, Robinson MT, McEvoy KM, Matsumoto JY, Lennon VA, Ahlskog JE, et al. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol. 2012;69:230–8. doi:10.1001/archneurol.2011.991.
37. Soderbergh A, Myhre AG, Ekwall O, Gebre-Medhin G, Hedstrand H, Landgren E, et al. Prevalence and Clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab. 2004;89:557–62. doi:10.1210/jc.2003-030279.
38. Lampasona V, Passerini L, Barzaghi F, Lombardoni C, Bazzigaluppi E, Brigatti C, et al. Autoantibodies to harmonin and villin are diagnostic markers in children with IPEX syndrome. PLoS One. 2013;8:e78664. doi:10.1371/journal.pone.0078664.
39. Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care. 2007;30:932–8. doi:10.2337/dc06-1696.
40. Solimena M, Dirkx R, Hermel JM, Pleasic-Williams S, Shapiro JA, Caron L, et al. ICA 512, an autoantigen of type I diabetes, is an intrinsic membrane protein of neurosecretory granules. EMBO J. 1996;15:2102–14.
41. Hu YF, Zhang HL, Cai T, Harashima S, Notkins AL. The IA-2 interactome. Diabetologia. 2005;48:2576–81. doi:10.1007/s00125-005-0037-y.
42. Trajkovski M, Mziaut H, Schubert S, Kalaidzidis Y, Altkrüger A, Solimena M. Regulation of insulin granule turnover in pancreatic beta-cells by cleaved ICA512. J Biol Chem. 2008;283:33719–29. doi:10.1074/jbc.M804928200.
43. Trajkovski M, Mziaut H, Altkrüger A, Ouwendijk J, Knoch K-P, Müller S, et al. Nuclear translocation of an ICA512 cytosolic fragment couples granule exocytosis and insulin expression in {beta}-cells. J Cell Biol. 2004;167:1063–74. doi:10.1083/jcb.200408172.
44. Mziaut H, Kersting S, Knoch K-P, Fan W-H, Trajkovski M, Erdmann K, et al. ICA512 signaling enhances pancreatic beta-cell proliferation by regulating cyclins D through STATs. Proc Natl Acad Sci U S A. 2008;105:674–9. doi:10.1073/pnas.0710931105.
45. Takeyama N, Ano Y, Wu G, Kubota N, Saeki K, Sakudo A, et al. Localization of insulinoma associated protein 2, IA-2 in mouse neuroendocrine tissues using two novel monoclonal antibodies. Life Sci. 2009;84:678–87. doi:10.1016/j.lfs.2009.02.012.
46. Diez J, Park Y, Zeller M, Brown D, Garza D, Ricordi C, et al. Differential splicing of the IA-2 mRNA in pancreas and lymphoid organs as a permissive genetic mechanism for autoimmunity against the IA-2 type 1 diabetes autoantigen. Diabetes. 2001;50:895–900.
47. Lampasona V, Bearzatto M, Genovese S, Bosi E, Ferrari M, Bonifacio E. Autoantibodies in insulin-dependent diabetes recognize distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen. J Immunol. 1996;157:2707–11.
48. Bearzatto M, Naserke H, Piquer S, Koczwara K, Lampasona V, Williams A, et al. Two distinctly HLA-associated contiguous linear epitopes uniquely expressed within the islet antigen 2 molecule are major autoantibody epitopes of the diabetes-specific tyrosine phosphatase-like protein autoantigens. J Immunol. 2002;168:4202–8.
49. Bearzatto M, Lampasona V, Belloni C, Bonifacio E. Fine mapping of diabetes-associated IA-2 specific autoantibodies. J Autoimmun. 2003;21:377–82.
50. Dromey JA, Weenink SM, Peters GH, Endl J, Tighe PJ, Todd I, et al. Mapping of epitopes for autoantibodies to the type 1 diabetes autoantigen IA-2 by peptide phage display and molecular modeling: overlap of antibody and T cell determinants. J Immunol. 2004;172:4084–90.
51. McLaughlin KA, Richardson CC, Williams S, Bonifacio E, Morgan D, Feltbower RG, et al. Relationships between major epitopes of the IA-2 autoantigen in type 1 diabetes: implications for determinant spreading. Clin Immunol. 2015;160:226–36. doi:10.1016/j.clim.2015.06.002.
52. Gylling M, Tuomi T, Björses P, Kontiainen S, Partanen J, Christie MR, et al. beta-cell autoantibodies, human leukocyte antigen II alleles, and type 1 diabetes in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin Endocrinol Metab. 2000;85:4434–40. doi:10.1210/jcem.85.12.7120.
53. Martino G, Grimaldi LM, Bazzigaluppi E, Passini N, Sinigaglia F, Rogge L. The insulin-dependent diabetes mellitus-associated ICA 105 autoantigen in stiff-man syndrome patients. J Neuroimmunol. 1996;69:129–34. doi:10.1016/0165-5728(96)00104-X.
54. Chimienti F, Devergnas S, Favier A, Seve M. Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. Diabetes. 2004;53:2330–7.
55. Lemaire K, Chimienti F, Schuit F. Zinc transporters and their role in the pancreatic β-cell. J Diabetes Investig. 2012;3:202–11. doi:10.1111/j.2040-1124.2012.00199.x.
56. Xu K, Zha M, Wu X, Yu Z, Yu R, Xu X, et al. Association between rs13266634 C/T polymorphisms of solute carrier family 30 member 8 (SLC30A8) and type 2 diabetes, impaired glucose tolerance, type 1 diabetes—a meta-analysis. Diabetes Res Clin Pract. 2011;91:195–202. doi:10.1016/j.diabres.2010.11.012.
57. Shan Z, Bao W, Zhang Y, Rong Y, Wang X, Jin Y, et al. Interactions between zinc transporter-8 gene (SLC30A8) and plasma zinc concentrations for impaired glucose regulation and type 2 diabetes. Diabetes. 2014;63:1796–803. doi:10.2337/db13-0606.
58. Kirchhoff K, Machicao F, Haupt A, Schäfer SA, Tschritter O, Staiger H, et al. Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia. 2008;51:597–601. doi:10.1007/s00125-008-0926-y.
59. Chimienti F, Devergnas S, Pattou F, Schuit F, Garcia-Cuenca R, Vandewalle B, et al. In vivo expression and functional characterization of the zinc transporter ZnT8 in glucose-induced insulin secretion. J Cell Sci. 2006;119:4199–206. doi:10.1242/jcs.03164.
60. Deniro M, Al-Mohanna FA. Zinc transporter 8 (ZnT8) expression is reduced by ischemic insults: a potential therapeutic target to prevent ischemic retinopathy. PLoS One. 2012;7:e50360. doi:10.1371/journal.pone.0050360.
61. Mohanasundaram D, Drogemuller C, Brealey J, Jessup CF, Milner C, Murgia C, et al. Ultrastructural analysis, zinc transporters, glucose transporters and hormones expression in New world primate (Callithrix jacchus) and human pancreatic islets. Gen Comp Endocrinol. 2011;174:71–9. doi:10.1016/j.ygcen.2011.07.004.
62. Wenzlau JM, Liu Y, Yu L, Moua O, Fowler KT, Rangasamy S, et al. A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes. 2008;57:2693–7. doi:10.2337/db08-0522.
63. Achenbach P, Lampasona V, Landherr U, Koczwara K, Krause S, Grallert H, et al. Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia. 2009;52:1881–8. doi:10.1007/s00125-009-1438-0.
64. Andersson C, Larsson K, Vaziri-Sani F, Lynch K, Carlsson A, Cedervall E, et al. The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes. Autoimmunity. 2011;44:394–405. doi:10.3109/08916934.2010.540604.
65. Rosenzweig JL, Havrankova J, Lesniak MA, Brownstein M, Roth J. Insulin is ubiquitous in extrapancreatic tissues of rats and humans. Proc Natl Acad Sci U S A. 1980;77:572–6. doi:10.1073/pnas.77.1.572.
66. Eng J, Yalow RS. Evidence against extrapancreatic insulin synthesis. Proc Natl Acad Sci U S A. 1981;78:4576–8. doi:10.1073/pnas.78.7.4576.
67. Pugliese A, Zeller M, Fernandez A, Zalcberg LJ, Bartlett RJ, Ricordi C, et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet. 1997;15:293–7. doi:10.1038/ng0397-293.
68. Vafiadis P, Bennett ST, Todd JA, Nadeau J, Grabs R, Goodyer CG, et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet. 1997;15:289–92. doi:10.1038/ng0397-289.
69. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler A-G, Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest. 2004;114:589–97. doi:10.1172/JCI21307.
70. Hall TR, Thomas JW, Padoa CJ, Torn C, Landin-Olsson M, Ortqvist E, et al. Longitudinal epitope analysis of insulin-binding antibodies in type 1 diabetes. Clin Exp Immunol. 2006;146:9–14. doi:10.1111/j.1365-2249.2006.03178.x.
71. Wong SL, Priestman A, Holmes DT. Recurrent hypoglycemia from insulin autoimmune syndrome. J Gen Intern Med. 2014;29:250–4. doi:10.1007/s11606-013-2588-9.
72. Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309:2473–9. doi:10.1001/jama.2013.6285. This study presents a combined analysis of islet autoimmunity markers and disease risk in all of the major ongoing prospective studies worldwide.
73. Giannopoulou EZ, Winkler C, Chmiel R, Matzke C, Scholz M, Beyerlein A, et al. Islet autoantibody phenotypes and incidence in children at increased risk for type 1 diabetes. Diabetologia. 2015;58:2317–23. doi:10.1007/s00125-015-3672-y.
74. Törn C, Hadley D, Lee H-S, Hagopian W, Lernmark Å, Simell O, et al. Role of type 1 diabetes-associated SNPs on risk of autoantibody positivity in the TEDDY Study. Diabetes. 2015;64:1818–29. doi:10.2337/db14-1497. This study presents a comprehensive analysis of genetic contribution to development of islet autoantibodies.
75. Hämäläinen AM, Ronkainen MS, Akerblom HK, Knip M. Postnatal elimination of transplacentally acquired disease-associated antibodies in infants born to families with type 1 diabetes. The Finnish TRIGR Study Group. Trial to reduce IDDM in the genetically at risk. J Clin Endocrinol Metab. 2000;85:4249–53. doi:10.1210/jcem.85.11.6987.
76. Naserke HE, Bonifacio E, Ziegler AG. Prevalence, characteristics and diabetes risk associated with transient maternally acquired islet antibodies and persistent islet antibodies in offspring of parents with type 1 diabetes. J Clin Endocrinol Metab. 2001;86:4826–33. doi:10.1210/jcem.86.10.7931.
77. Krischer JP, Lynch KF, Schatz DA, Ilonen J, Lernmark Å, Hagopian WA, et al. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia. 2015;58:980–7. doi:10.1007/s00125-015-3514-y.
78. Ziegler A-G, Bonifacio E. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia. 2012;55:1937–43. doi:10.1007/s00125-012-2472-x.
79. Chmiel R, Giannopoulou EZ, Winkler C, Achenbach P, Ziegler A-G, Bonifacio E. Progression from single to multiple islet autoantibodies often occurs soon after seroconversion: implications for early screening. Diabetologia. 2015;58:411–3. doi:10.1007/s00125-014-3443-1.
80. Steck AK, Vehik K, Bonifacio E, Lernmark A, Ziegler A-G, Hagopian WA, et al. Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY). Diabetes Care. 2015;38:808–13. doi:10.2337/dc14-2426. This study presents an updated analysis of the contribution of islet autoantibody combinations and titers to T1D risk.
81. Bonifacio E, Scirpoli M, Kredel K, Füchtenbusch M, Ziegler AG. Early autoantibody responses in prediabetes are IgG1 dominated and suggest antigen-specific regulation. J Immunol. 1999;163:525–32.
82. Hawa MI, Fava D, Medici F, Deng YJ, Notkins AL, De Mattia G, et al. Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care. 2000;23:228–33. doi:10.1128/AAC.03728-14.
83. Seissler J, Eikamp K, Schott M, Scherbaum WA, DENIS Study Group. IA-2 autoantibodies restricted to the IgG4 subclass are associated with protection from type 1 diabetes. Horm Metab Res. 2002;34:186–91. doi:10.1055/s-2002-26708.
84. Hoppu S, Ronkainen MS, Kimpimäki T, Simell S, Korhonen S, Ilonen J, et al. Insulin autoantibody isotypes during the prediabetic process in young children with increased genetic risk of type 1 diabetes. Pediatr Res. 2004;55:236–42. doi:10.1203/01.PDR.0000100905.41131.3F.
85. Achenbach P, Warncke K, Reiter J, Naserke HE, Williams AJK, Bingley PJ, et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes. 2004;53:384–92. doi:10.2337/diabetes.53.2.384.
86. A.J.K. Williams, V. Lampasona, M. Schlosser, P.W. Mueller, D. Pittman, W.E. Winter RW, B. Akolkar, P.J. Bingley1 PA. N-terminally truncated GAD discriminates progression in GAD antibody positive relatives of patients with type 1 diabetes. Diabetologia. 2013;65:56.
87. Williams AJK, Lampasona V, Wyatt R, Brigatti C, Gillespie KM, Bingley PJ, et al. Reactivity to N-terminally truncated GAD65(96-585) identifies GAD autoantibodies that are more closely associated with diabetes progression in relatives of patients with type 1 diabetes. Diabetes. 2015;64:3247–52. doi:10.2337/db14-1694.
88. Williams AJK, Lampasona V, Schlosser M, Mueller PW, Pittman DL, Winter WE, et al. Detection of antibodies directed to the N-terminal region of GAD is dependent on assay format and contributes to differences in the specificity of GAD autoantibody assays for type 1 diabetes. Diabetes. 2015;64:3239–46. doi:10.2337/db14-1693.
89. Achenbach P, Bonifacio E, Williams AJK, Ziegler AG, Gale EAM, Bingley PJ, et al. Autoantibodies to IA-2beta improve diabetes risk assessment in high-risk relatives. Diabetologia. 2008;51:488–92. doi:10.1007/s00125-007-0912-9.
90. De Grijse J, Asanghanwa M, Nouthe B, Albrecher N, Goubert P, Vermeulen I, et al. Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials. Diabetologia. 2010;53:517–24. doi:10.1007/s00125-009-1618-y.
91. Naserke HE, Ziegler AG, Lampasona V, Bonifacio E. Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes. J Immunol. 1998;161:6963–9.
92. Mayr A, Schlosser M, Grober N, Kenk H, Ziegler AG, Bonifacio E, et al. GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for type 1 diabetes. Diabetes. 2007;56:1527–33. doi:10.2337/db06-1715.
93. Bender C, Schlosser M, Christen U, Ziegler AG, Achenbach P. GAD autoantibody affinity in schoolchildren from the general population. Diabetologia. 2014;57:1911–8. doi:10.1007/s00125-014-3294-9.
94. Achenbach P, Schlosser M, Williams AJK, Yu L, Mueller PW, Bingley PJ, et al. Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program. Clin Immunol. 2007;122:85–90. doi:10.1016/j.clim.2006.09.004.
95. Krause S, Chmiel R, Bonifacio E, Scholz M, Powell M, Furmaniak J, et al. IA-2 autoantibody affinity in children at risk for type 1 diabetes. Clin Immunol. 2012;145:224–9. doi:10.1016/j.clim.2012.09.010.
96. Arif S, Leete P, Nguyen V, Marks K, Nor NM, Estorninho M, et al. Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes. 2014;63:3835–45. doi:10.2337/db14-0365. This paper present striking data regarding the existence of diverse sub-types of islet autoimmunity in T1D.
97. Skyler JS. Characterizing subgroups of type 1 diabetes. Diabetes. 2014;63:3578–80. doi:10.2337/db14-1160.
98. Thompson WS, Pekalski ML, Simons HZ, Smyth DJ, Castro-Dopico X, Guo H, et al. Multi-parametric flow cytometric and genetic investigation of the peripheral B cell compartment in human type 1 diabetes. Clin Exp Immunol. 2014;177:571–85. doi:10.1111/cei.12362.
99. Kawasaki E, Yu L, Rewers M, Hutton J, Eisenbarth G. Definition of multiple ICA512/phogrin autoantibody epitopes and detection of intramolecular epitope spreading in relatives of patients with type 1 diabetes. Diabetes. 1998;47:733–42. doi:10.2337/diabetes.47.5.733.
100. Jayakrishnan B, Hoke DE, Langendorf CG, Buckle AM, Rowley MJ. An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes. PLoS One. 2011;6:e18411. doi:10.1371/journal.pone.0018411.
101. Keenan HA, Sun JK, Levine J, Doria A, Aiello LP, Eisenbarth G, et al. Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes. 2010;59:2846–53. doi:10.2337/db10-0676.
102. Richardson CC, Dromey JA, McLaughlin KA, Morgan D, Bodansky HJ, Feltbower RG, et al. High frequency of autoantibodies in patients with long duration type 1 diabetes. Diabetologia. 2013;14:2538–40. doi:10.1007/s00125-013-3017-7.
103. Tridgell DM, Spiekerman C, Wang RS, Greenbaum CJ. Interaction of onset and duration of diabetes on the percent of GAD antibody and insulinoma-antigen 2 antibodies-positive subjects in the Type 1 Diabetes Genetic Consortium Database. Diabetes Care. 2011. doi:10.2337/dc10-1903.
104. Roep BO, Stobbe I, Duinkerken G, van Rood JJ, Lernmark A, Keymeulen B, et al. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes. 1999;48:484–90.
105. Braghi S, Bonifacio E, Secchi A, Di Carlo V, Pozza G, Bosi E. Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes. Diabetes. 2000;49:218–24.
106. Bosi E, Braghi S, Maffi P, Scirpoli M, Bertuzzi F, Pozza G, et al. Autoantibody response to islet transplantation in type 1 diabetes. Diabetes. 2001;50:2464–71.
107. Madaschi S, Rossini A, Formenti I, Lampasona V, Marzoli SB, Cammarata G, et al. Treatment of thyroid-associated orbitopathy with rituximab—a novel therapy for an old disease: case report and literature review. Endocr Pract. 2010;16:677–85. doi:10.4158/EP09385.RA.
108. Demeester S, Keymeulen B, Kaufman L, Van Dalem A, Balti EV, Van de Velde U, et al. Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes. Diabetes Care. 2015;38:644–51. doi:10.2337/dc14-1575.